J.P. Morgan analyst Jessica Fye has maintained their bullish stance on BMRN stock, giving a Buy rating today.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Jessica Fye’s rating is based on several key considerations regarding BioMarin Pharmaceutical’s current and future prospects. Despite a slight miss in third-quarter revenues, particularly with Voxzogo, management has adjusted their 2025 revenue guidance upwards, indicating confidence in future performance. The removal of the 2027 revenue target, while initially concerning, aligns with market expectations and reflects a realistic approach to future projections.
Moreover, BioMarin’s underlying business is seen as undervalued, with a strong base and potential for growth despite current market skepticism. The company is strategically positioned with a robust pipeline and significant capital for business development, focusing on late-stage assets to drive sustainable growth. This combination of factors, including a healthy enzyme revenue stream and promising developments in their pipeline, supports the Buy rating given by Jessica Fye.
In another report released today, Barclays also maintained a Buy rating on the stock with a $80.00 price target.